Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

CANF Can Fite BioPharma Ltd

2,455

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 15:26:47

Verzögert um 15 Minuten

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

null

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Can Fite BioPharma Charts.

Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Can Fite BioPharma Charts.

News Can Fite BioPharma Ltd

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 13 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
Montag 13 Mai 2024 (1 Woche vor) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 9 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
Donnerstag 9 Mai 2024 (2 Wochen vor) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 6 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
Montag 6 Mai 2024 (2 Wochen vor) • Business Wire

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Donnerstag 25 April 2024 (4 Wochen vor) • Business Wire

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Montag 15 April 2024 (1 Monat vor) • Business Wire

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Mittwoch 3 April 2024 (2 Monate vor) • Business Wire

Can-Fite Reports 2023 Financial Results and Clinical Update
Donnerstag 28 März 2024 (2 Monate vor) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Montag 11 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Montag 11 März 2024 (2 Monate vor) • Business Wire

Weitere Can Fite BioPharma Ltd News-Artikel

Euro vs Sterling

Health Care Select Sector

Deutsche Telekom

BNP Paribas (QX)

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen